Intellia Therapeutics Stock Analysis
| NTLA Stock | USD 12.27 0.85 6.48% |
Intellia Therapeutics is overvalued with Real Value of 11.78 and Target Price of 31.48. The main objective of Intellia Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Intellia Therapeutics is worth, separate from its market price. There are two main types of Intellia Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Intellia Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Intellia Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. Intellia Stock Analysis Notes
About 88.0% of the company shares are owned by institutional investors. The book value of Intellia Therapeutics was now reported as 6.79. The company recorded a loss per share of 4.69. Intellia Therapeutics had not issued any dividends in recent years. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Intellia Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 485 people. To find out more about Intellia Therapeutics contact John MD at 857 285 6200 or learn more at https://www.intelliatx.com.Intellia Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Intellia Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Intellia Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Intellia Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 57.88 M. Net Loss for the year was (519.02 M) with loss before overhead, payroll, taxes, and interest of (387.25 M). | |
| Intellia Therapeutics currently holds about 874.28 M in cash with (348.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.5. | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from fool.com: Why Dyne Therapeutics Stock Crushed the Market on Monday |
Intellia Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intellia Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Intellia Largest EPS Surprises
Earnings surprises can significantly impact Intellia Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-10-31 | 2017-09-30 | -0.5 | -0.44 | 0.06 | 12 | ||
2018-05-01 | 2018-03-31 | -0.58 | -0.51 | 0.07 | 12 | ||
2020-08-06 | 2020-06-30 | -0.69 | -0.61 | 0.08 | 11 |
Intellia Therapeutics Environmental, Social, and Governance (ESG) Scores
Intellia Therapeutics' ESG score is a quantitative measure that evaluates Intellia Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Intellia Therapeutics' operations that may have significant financial implications and affect Intellia Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Intellia Stock Institutional Investors
| Shares | Two Sigma Advisers, Llc | 2025-06-30 | 2.1 M | Goldman Sachs Group Inc | 2025-06-30 | 2 M | Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.9 M | Voloridge Investment Management, Llc | 2025-06-30 | 1.6 M | Contrarius Group Holdings Ltd | 2025-06-30 | 1.6 M | Fmr Inc | 2025-06-30 | 1.5 M | Balyasny Asset Management Llc | 2025-06-30 | 1.3 M | Woodline Partners Lp | 2025-06-30 | 1.2 M | Trexquant Investment Lp | 2025-06-30 | 1.1 M | Ark Investment Management Llc | 2025-06-30 | 13 M | Vanguard Group Inc | 2025-06-30 | 10.9 M |
Intellia Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.32 B.Intellia Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.60) | (0.62) |
Management Efficiency
Intellia Therapeutics has return on total asset (ROA) of (0.3062) % which means that it has lost $0.3062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5695) %, meaning that it created substantial loss on money invested by shareholders. Intellia Therapeutics' management efficiency ratios could be used to measure how well Intellia Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of October 31, 2025, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.52. At present, Intellia Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 578.7 M, whereas Total Assets are forecasted to decline to about 743.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.82 | 6.69 | |
| Tangible Book Value Per Share | 8.82 | 6.69 | |
| Enterprise Value Over EBITDA | (2.24) | (2.35) | |
| Price Book Value Ratio | 1.32 | 1.26 | |
| Enterprise Value Multiple | (2.24) | (2.35) | |
| Price Fair Value | 1.32 | 1.26 | |
| Enterprise Value | 195.8 M | 174 M |
The decision-making processes within Intellia Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Technical Drivers
As of the 31st of October, Intellia Therapeutics retains the Downside Deviation of 8.36, market risk adjusted performance of 0.5895, and Risk Adjusted Performance of 0.0374. Concerning fundamental indicators, the technical analysis model lets you check existing technical drivers of Intellia Therapeutics, as well as the relationship between them.Intellia Therapeutics Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Moving Average is predictive technique used to analyze Intellia Therapeutics price data points by creating a series of averages of different subsets of Intellia Therapeutics entire price series.
Intellia Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intellia Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intellia Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intellia Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Intellia Therapeutics Outstanding Bonds
Intellia Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Intellia Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Intellia bonds can be classified according to their maturity, which is the date when Intellia Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Intellia Therapeutics Predictive Daily Indicators
Intellia Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Intellia Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Intellia Therapeutics Corporate Filings
8K | 29th of October 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 27th of October 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of October 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 25th of September 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 22nd of August 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 7th of August 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 25th of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 3rd of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Intellia Therapeutics Forecast Models
Intellia Therapeutics' time-series forecasting models are one of many Intellia Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Intellia Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Intellia Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Intellia Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Intellia shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Intellia Therapeutics. By using and applying Intellia Stock analysis, traders can create a robust methodology for identifying Intellia entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (8.97) | (9.42) | |
| Operating Profit Margin | (9.23) | (9.69) | |
| Net Loss | (8.97) | (9.42) | |
| Gross Profit Margin | 0.82 | 0.86 |
Current Intellia Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Intellia analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Intellia analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 31.48 | Strong Buy | 29 | Odds |
Most Intellia analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Intellia stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Intellia Therapeutics, talking to its executives and customers, or listening to Intellia conference calls.
Intellia Stock Analysis Indicators
Intellia Therapeutics stock analysis indicators help investors evaluate how Intellia Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Intellia Therapeutics shares will generate the highest return on investment. By understating and applying Intellia Therapeutics stock analysis, traders can identify Intellia Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 240.4 M | |
| Common Stock Shares Outstanding | 98.8 M | |
| Total Stockholder Equity | 872 M | |
| Total Cashflows From Investing Activities | 125.6 M | |
| Property Plant And Equipment Net | 246.7 M | |
| Cash And Short Term Investments | 601.5 M | |
| Cash | 189.2 M | |
| Accounts Payable | 14.6 M | |
| Net Debt | 21 M | |
| 50 Day M A | 17.0511 | |
| Total Current Liabilities | 110.9 M | |
| Other Operating Expenses | 592.1 M | |
| Non Current Assets Total | 551.2 M | |
| Non Currrent Assets Other | 260.2 M | |
| Stock Based Compensation | 154.3 M |
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |